COVID-19: India’s first intranasal vaccine by Bharat Biotech gets drug panel’s nod for ‘restricted use’

By Rose On Sep 6, 2022

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for ‘restricted use in an emergency situation’

New Delhi: A nasal vaccine against COVID-19, developed by Covaxin-maker Bharat Biotech has been approved for “restricted use” by India’s top drug controller, Union health minister Mansukh Mandaviya said on Tuesday.

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for “restricted use in an emergency situation.”

Big Boost to India’s Fight Against COVID-19!

Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.

— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

The union health minister also said that India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM
Narendra Modi’s leadership.

With inputs from agencies

Read all the Latest News, Trending News, Cricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

For all the latest health News Click Here

Read original article here

Denial of responsibility! TechAI is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.